The Biotech Investment Act
Executive Summary
The Homeland Investment Act will allow Big Pharma to bring into the US a huge horde of foreign earnings at very attractive tax rates. Given the pipeline drought, some of that money is going to go to biotechs.
You may also be interested in...
NovaCardia & Domain: New-Model Spec Pharma Investing
Domain partner Eckard Weber has become a master of the one-two punch in venture investing. The process (now in its third iteration following Merck's $350 million acquisition of NovaCardia): find a drug no one cares about; create a low-infrastructure company around it; find a second drug; sell off the lead drug through an acquisition; develop the second drug a bit more with the same management; then sell that one too. The first deal at a minimum pays back the investors; the second deal juices the returns. It's a model many VCs want to follow.
Move Over Late-Stage Alliances; Enter Acquisitions
The higher the cost of late-stage alliances, the likelier acquisitions are. And that's just what our statistical view of significant acquisitions is showing--the number of $100mm-plus biotech acquisitions has increased dramatically over the last half-decade, including an increasing percentage from Big Pharma.
The Better Exit for Private Biotechs: M&A
Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.